-DT&CRO, DT&Nedicals, Hue Science, Safesoft, ’emphasis on customized Full-CRO service’
– Establish CRO strategy with DTNCRO and contacts
-Continue detailed discussions such as scale of facility and types of animals…
– Additional meeting arranged at ‘Tokyo-Interpex’ in July
-We will continue to participate in global exhibitions in the future and ‘grow up’ as ‘CRO Bio Group’
[앵커]
Although it is the first to participate in BioUSA, the DTNC Bio Group, which achieved the results of a business agreement and confirmed its growth potential in the global market, plans to continue its global meeting at the Interpex which coming in Tokyo. Reporter Kim Hyo-sun summarized the achievements of the DTNC Bio Group.
[기자]
Grŵp Bio DTNC has been busy with the schedule since day one.
We managed to hold meetings with global CRO companies, as well as a front-bridge role for Korean companies to join the global market.
[조권/ 휴사이언스 부사장]
“It’s not just the clinical CRO. The requested parts are non-clinical data in Korea, data that was simply analyzed for clinical trials, and if it goes through Avance Clinical, it’s easy to go to FDA the United States or Europe. We believe that our bio-group will become a leader to go abroad as a whole.”
In this way, DNTNCRO and all of its affiliates are in a position to review non-clinical and clinical data together and establish strategies so that Korean bio-enterprise companies can successfully enter Australia and the Americas.
In addition, the website showed the most interest in synergies and total services with related companies such as DTNCRO. In particular, the participants showed great interest in the test areas that can be specifically responded to, the types of animals, and the size of the facilities.
[이동훈/세이프소프트 대표]
“What Japanese companies are asking for this time is a structure that has no choice but to use CRO services and non-clinical trial efficacy services. They seem to be looking for more opportunities to license out of the Japanese side by using those We will promote our group and continue to increase our value as a global clinical company… (planned)”
[스탠딩]
The company is evaluated to have confirmed its position in the global market during the BioUSA four-day schedule. He also promised to do his best to ensure tangible results at Interpex held in Japan.
I’m Kim Hyo-sun from Pax Economy TV on the Bio USA site in Boston, USA.
Copyright © Pax Economy TV Unauthorized reproduction and redistribution prohibited
